1. Oster G, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. Journal of Pain 2005; 6: 356–363.
2. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. British Medical Journal 2003; 326: 748–750.
3. Jung BF, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545–1551.
4. Schmader K. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain 2002; 18: 350–354.
5. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Reviews in Medical Microbiology, 1993; 4: 222–230.
6. Brisson M, et al. Epidemiology of varicella zoster virus infection in Canada and in the United Kingdom. Epidemiology and Infection 2001; 27: 305–314.
7. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. British Medical Journal 2000; 321: 778–779.
8. Donahue JG, et al. The incidence of herpes zoster. Archives of Internal Medicine 1995; 155: 1605–1609.
9. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. European Journal of Pain 1999; 3: 335–342.
10. Edmunds J, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19: 3076–3090.
11. Opstelten W, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Family Practice 2002; 19: 471–475.
12. Scott FT, et al. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006; 24: 1308–1314.
13. Hope-Simpson R. Postherpetic neuralgia. Journal of Royal College of General Practitioners 1975; 18: 25–33.
14. Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 2271–2284.
16. Curtis L, Netten A. Unit Costs and Health and Social Services 2005. Personal Social Services Research Unit, 2005.
20. Insinga R, et al. The incidence of Herpes Zoster in a United States Administrative Database. Journal of General Internal Medicine 2005; 230: 748–753.
21. Thomas S, Hall A. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infectious Diseases 2004; 4: 26–33.
22. Bebbington A, Darton R, Netten A. Care homes for older people, volume 2. Admissions, needs and outcomes. The 1995/96 National Longitudinal Survey of Publicly-Funded Admissions PSSRU (http://www.pssru.ac.uk/pdf/chop2.pdf). Accessed 13 February 2008.
23. Alper B, Lewis P. Does treatment of acute Herpes Zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature. Family Practice 2000; 49: 255–264.
24. Opstelten W et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Annals of Epidemiology 2006; 16: 692–695.
25. Fleming D, et al. Gender difference in the incidence of shingles. Epidemiology and Infection 2004; 132: 1–5.
26. Coplan PM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. Journal of Pain 2004; 5: 344–356.
27. Chidiac C, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clinical Infectious Diseases 2001; 33: 62–69.
28. Davies L, et al. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics 1994; 6: 142–148.
29. Katz J, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clinical Infectious Diseases 2004; 39: 342–348.